

A Pterin-Dependent Signaling Pathway Regulates a Dual-Function Diguanylate Cyclase-Phosphodiesterase Controlling Surface Attachment in *Agrobacterium tumefaciens*

Nathan Feirer,^a Jing Xu,^a Kylie D. Allen,^c Benjamin J. Koestler,^b Eric L. Bruger,^b Christopher M. Waters,^b Robert H. White,^c Clay Fuqua^a

Department of Biology, Indiana University, Bloomington, Indiana, USA^a; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA^b; Department of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA^c

ABSTRACT The motile-to-sessile transition is an important lifestyle switch in diverse bacteria and is often regulated by the intracellular second messenger cyclic diguanylate monophosphate (c-di-GMP). In general, high c-di-GMP concentrations promote attachment to surfaces, whereas cells with low levels of signal remain motile. In the plant pathogen *Agrobacterium tumefaciens*, c-di-GMP controls attachment and biofilm formation via regulation of a unipolar polysaccharide (UPP) adhesin. The levels of c-di-GMP in *A. tumefaciens* are controlled in part by the dual-function diguanylate cyclase-phosphodiesterase (DGC-PDE) protein DcpA. In this study, we report that DcpA possesses both c-di-GMP synthesizing and degrading activities in heterologous and native genetic backgrounds, a binary capability that is unusual among GGDEF-EAL domain-containing proteins. DcpA activity is modulated by a pteridine reductase called PruA, with DcpA acting as a PDE in the presence of PruA and a DGC in its absence. PruA enzymatic activity is required for the control of DcpA and through this control, attachment and biofilm formation. Intracellular pterin analysis demonstrates that PruA is responsible for the production of a novel pterin species. In addition, the control of DcpA activity also requires PruR, a protein encoded directly upstream of DcpA with a predicted molybdopterin-binding domain. PruR is hypothesized to be a potential signaling intermediate between PruA and DcpA through an as-yet-unidentified mechanism. This study provides the first prokaryotic example of a pterin-mediated signaling pathway and a new model for the regulation of dual-function DGC-PDE proteins.

IMPORTANCE Pathogenic bacteria often attach to surfaces and form multicellular communities called biofilms. Biofilms are inherently resilient and can be difficult to treat, resisting common antimicrobials. Understanding how bacterial cells transition to the biofilm lifestyle is essential in developing new therapeutic strategies. We have characterized a novel signaling pathway that plays a dominant role in the regulation of biofilm formation in the model pathogen *Agrobacterium tumefaciens*. This control pathway involves small metabolites called pterins, well studied in eukaryotes, but this is the first example of pterin-dependent signaling in bacteria. The described pathway controls levels of an important intracellular second messenger (cyclic diguanylate monophosphate) that regulates key bacterial processes such as biofilm formation, motility, and virulence. Pterins control the balance of activity for an enzyme that both synthesizes and degrades the second messenger. These findings reveal a complex, multistep pathway that modulates this enzyme, possibly identifying new targets for antibacterial intervention.

Received 5 February 2015 Accepted 3 June 2015 Published 30 June 2015

Citation Feirer N, Xu J, Allen KD, Koestler BJ, Bruger EL, Waters CM, White RH, Fuqua C. 2015. A pterin-dependent signaling pathway regulates a dual-function diguanylate cyclase-phosphodiesterase controlling surface attachment in *Agrobacterium tumefaciens*. *mBio* 6(4):e00156-15. doi:10.1128/mBio.00156-15.

Invited Editor Matthew R. Parsek, University of Washington **Editor** E. Peter Greenberg, University of Washington

Copyright © 2015 Feirer et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license](https://creativecommons.org/licenses/by-nc-sa/4.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited.

Address correspondence to Clay Fuqua, cfuqua@indiana.edu.

Bacterial cells often exist as members of multicellular communities known as biofilms, which are commonly formed by both commensal and pathogenic bacteria (1, 2). Bacteria within a biofilm are encased within a complex extracellular matrix (3) that often provides protection against toxic substances (4, 5) and desiccation (6) and facilitates nutrient exchange (7). Biofilms are difficult to control due to their intrinsic antibiotic tolerance (8). Therapeutic intervention targeting bacterial attachment and the subsequent steps that lead to biofilm formation could hold promise in treating a variety of bacterial infections. Understanding how these bacteria orchestrate the transition from a motile, free-living lifestyle to a sessile, multicellular biofilm is a major goal of recent research.

Cyclic diguanylate monophosphate (c-di-GMP) is a nucleotide second messenger (9, 10) that plays a critical role in the regulation of bacterial attachment and biofilm formation in diverse bacteria. Since its discovery over 25 years ago (11), c-di-GMP has been implicated in controlling processes intimately associated with biofilm formation such as polysaccharide biosynthesis (12, 13), production and transport of biofilm matrix components (14, 15), oxygen-dependent regulation (16), and motility (17). In addition, c-di-GMP can also control virulence (18, 19) and morphological development (20, 21). Intracellular c-di-GMP levels are perceived through several varieties of c-di-GMP-responsive receptors, enzyme allosteric sites, transcription factors, and ribo-

switches (19, 22–25). Elevated levels of *c*-di-GMP typically favor the sessile state, resulting in increased attachment and biofilm formation, whereas lower levels of *c*-di-GMP favor the motile, planktonic state and the downregulation of attachment (10).

The *c*-di-GMP concentration within a cell is controlled by the opposing activities of diguanylate cyclases (DGCs) and phosphodiesterases (PDEs), which possess synthetic and degradative activities, respectively (10, 26). DGCs are characterized by the GGDEF catalytic motif (21), and PDEs are characterized by either an EAL (27, 28) or HD-GYP catalytic motif (29). Proteins with both GGDEF and EAL domains are common, but in many examples, one of the domains is catalytically inactive (30, 31). There are few examples of enzymes that are known to have both DGC and PDE activities (32–35), and their *in vivo* regulation and activity are poorly understood (36–38).

Agrobacterium tumefaciens is a facultative plant pathogen that causes the neoplastic disease called crown gall via cross-kingdom horizontal gene transfer and integration of plasmid-derived tumorigenic DNA into the plant genome (39–41). *A. tumefaciens* forms biofilms on both biotic and abiotic surfaces (42, 43), with attachment to the plant surface as a required component of plant transformation. Attachment to a range of surfaces is dependent upon the unipolar polysaccharide (UPP) adhesin (44, 45) with additional influence from cellulose (46, 47). Regulation of *A. tumefaciens* attachment is controlled by multiple integrated regulatory pathways (48), several of which play a role in modulating intracellular *c*-di-GMP levels.

Shortly after its original discovery, the presence of *c*-di-GMP was detected in *A. tumefaciens*, and its role in the regulation of cellulose synthesis was described (13). This regulation was recently attributed, at least in part, to a DGC in *A. tumefaciens* (49, 50) that is homologous to the well-studied PleD GGDEF protein from *Caulobacter crescentus*. The levels of *c*-di-GMP have also been shown to directly regulate attachment, with elevated *c*-di-GMP concentrations driven by overexpression of the *A. tumefaciens* PleD leading to increased levels of UPP production, cellulose synthesis, and biofilm formation (50). Despite these observations, little is known about how *c*-di-GMP signaling is integrated into the overall regulatory network for controlling attachment and biofilm formation in *A. tumefaciens*.

In the search for regulatory candidates, a transposon mutagenesis screen was performed for mutants that mimicked the elevated UPP production phenotype of a PleD-overexpressing strain (50). Several classes of transposon mutations were described, including the *visNR* locus, encoding the master motility regulators in *A. tumefaciens*, now known to inhibit *c*-di-GMP synthesis through two DGC proteins that do not include PleD. Two other intriguing mutant classes included a putative pteridine reductase (Atu1130, designated here as PruA) and a dual GGDEF-EAL protein (Atu3495, now designated DcpA [diguanylate cyclase/phosphodiesterase A]). Transposon mutations in either *dcpA* or *pruA* led to increased staining with the polysaccharide-reactive dye Congo red (reporting on UPP and cellulose production) and elevated attachment and biofilm formation (50), suggesting that these genes are negative regulators of *A. tumefaciens* surface interactions. It was hypothesized that a loss of DcpA PDE function might lead to increased UPP and cellulose production through elevated levels of *c*-di-GMP.

In this study, the PDE activity of DcpA is shown to be necessary for the negative regulation of attachment. However, DcpA can

also act as a DGC, implicating DcpA as a dual-function DGC-PDE protein. The primary state of DcpA activity in *A. tumefaciens* is regulated via a complex control pathway that involves the production of a low-molecular-weight metabolite known as a pterin, a class of redox-reactive enzymatic prosthetic groups, by a putative pteridine reductase (PruA). This control of DcpA influences UPP and cellulose production, attachment, and biofilm formation of *A. tumefaciens*. The pterin produced by PruA requires a putative pterin-binding protein PruR, encoded immediately upstream of DcpA, to influence DcpA activity, establishing a mechanism by which pterin-dependent signaling modulates the balance between motile to sessile growth modes for *A. tumefaciens*.

RESULTS

Genetic and phenotypic evidence for DcpA phosphodiesterase and diguanylate cyclase activity. Our previous studies suggested that the Atu3495 gene product (now designated DcpA), which contains highly conserved GGDEF and EAL domains, acts as a phosphodiesterase (PDE) in wild-type *A. tumefaciens* based on several surface attachment-associated phenotypes of a *dcpA* in-frame deletion mutant (50). The DcpA coding sequence is 1,935 bp and is located on the *A. tumefaciens* C58 linear chromosome, 8 bp downstream of a predicted open reading frame coding for the conserved hypothetical protein Atu3496. Hence, these two genes are likely to form an operon (Fig. 1A). Atu3496 and its potential relationship to DcpA will be described below. Upstream of the Atu3496 gene and separated by 181 bp is the Atu3497 gene, which encodes a conserved hypothetical protein with no recognized domains.

The N terminus of DcpA contains a predicted periplasmic region of approximately 140 amino acid (aa) residues flanked by two transmembrane domains (Fig. 1B). It is possible that this periplasmic segment plays a sensory function, but the region is not homologous to any known protein domains. A predicted DGC domain (residues 226 to 381) lies carboxy terminal to the periplasmic domain. This domain contains a GGDEF motif and other conserved residues needed for proper enzymatic activity of canonical DGC proteins, such as those involved in GTP and metal binding (see Fig. S1A in the supplemental material) (23, 51). Notably, DcpA lacks a conserved RXXD I-site motif, which is normally involved in negative allosteric feedback of *c*-di-GMP synthesis (23). The PDE domain of DcpA (residues 400 to 672) is composed of a canonical EAL catalytic motif and other essential residues necessary for metal coordination (Fig. S1B). In summary, DcpA has all the necessary residues consistent with enzymatically active DGC and PDE domains and is named *dcpA* (for diguanylate cyclase/phosphodiesterase A).

In order to delve further into the mechanistic basis for the aforementioned phenotypes and to genetically test DcpA's role as a PDE, a targeted mutation (E431A) was constructed to change the EAL catalytic motif to AAL. In parallel and in combination with the EAL mutation, the GGDEF catalytic motif of DcpA was mutated to GGDAF (E308A). These mutations have been reported to enzymatically inactivate PDE domains and DGC domains, respectively (26, 27, 50, 52).

A wild-type copy of *dcpA* provided on a plasmid expressed from the *lacZ* promoter (P_{lac} -*dcpA*; DGC+PDE+) was introduced into a Δ *dcpA* mutant, and when it was induced with isopropyl- β -D-thiogalactopyranoside (IPTG), it diminished biofilm formation of the Δ *dcpA* mutant (Fig. 1C, P value of <0.05 by




FIG 1 Complementation of increased biofilm formation in the *A. tumefaciens* *dcpA* mutant requires an intact DcpA EAL catalytic motif. (A) Diagram of PruR-DcpA genetic locus. Atu3497 is a conserved hypothetical protein with no annotated domains. (B) Protein topology of DcpA. Protein domains predicted by the BLAST database (NCBI) are shown. Domains are drawn to scale. TM, transmembrane; DGC, diguanylate cyclase; PDE, phosphodiesterase. (C) *A. tumefaciens* quantitative biofilm formation on PVC coverslips after 48 h of static growth at 28°C. Adherent biomass was quantified by staining with crystal violet (CV). CV absorbance was quantified by absorbance at 600 nm (A_{600}). In parallel, the optical density at 600 nm (OD_{600}) of planktonic culture was determined. CV absorbance was normalized to culture growth by calculating the A_{600}/OD_{600} ratio. IPTG (400 μ M) was added to all strains. The wild-type (WT) strain, $\Delta dcpA$ mutant with no plasmid inserted (-), and $\Delta dcpA$ mutant strain with P_{lac} -*dcpA* derivatives are shown. A wild-type copy of *dcpA* provided on a plasmid expressed from the *lacZ* promoter (P_{lac} -*dcpA*; DGC⁺PDE⁺) was introduced into a $\Delta dcpA$ mutant. The P_{lac} -*dcpA* derivatives include a DcpA variant containing catalytic site GGDEF→GGDAF mutation (DGC⁻) and a DcpA variant containing catalytic site EAL→AAL mutation (PDE⁻). Values are results of three independent biological replicates consisting of three technical replicates each. The error bars show 1 standard deviation (SD).

paired *t* test) and Congo red staining, reflecting polysaccharide levels, to near wild-type (WT) levels (see Fig. S2A in the supplemental material). Decreased biofilm formation was responsive to increasing levels of IPTG (Fig. S2B). Mutating the GGDEF catalytic motif (E308A) had no effect on the ability of *dcpA* to complement the null mutation (Fig. 1C, *P* value of <0.05 by paired *t* test compared to the value for the WT). However, mutation of the EAL motif in the PDE domain (E431A) alone abolished the ability of *dcpA* to complement the mutant biofilm phenotype back to WT levels, and this plasmid in fact stimulated biofilm formation approximately 10-fold greater than that observed in the $\Delta dcpA$ mutant (Fig. 1C, *P* value of <0.05 by paired *t* test). This

elevated level of biofilm formation is due to a functional GGDEF motif, as the plasmid-borne *dcpA* double mutant (E308A E431A) did not elevate biofilm levels above the $\Delta dcpA$ mutant (Fig. 1C). The phenotypes of the PDE disabled *dcpA* variant were not multicopy effects, as the mutation introduced into the native copy of *dcpA* resulted in the same phenotypes as the plasmid-borne allele (Fig. S2A and data not shown). Direct measurement of *c*-di-GMP in whole-cell extracts revealed that the $\Delta dcpA$ mutant tended to be slightly elevated, but these values were not statistically different from wild-type *A. tumefaciens* (Fig. S3A, *P* value of 0.09 by paired *t* test).

The impact of the *dcpA* mutations on biofilm formation, Congo red staining, and *c*-di-GMP levels in the wild-type strain was determined. Providing the plasmid-borne *dcpA* gene in the wild-type background depressed levels of biofilm formation (Fig. 2A, *P* value of <0.05 by paired *t* test compared to the WT value). Slight, nonsignificant decreases in Congo red staining and *c*-di-GMP concentrations (*P* value of 0.12 by paired *t* test compared to the WT value) were also observed (Fig. 2B and C). Introduction of the *dcpA* GGDEF motif (E308A) mutant plasmid (DGC⁻PDE⁺) resulted in a similar decrease (*P* value of 0.05 by paired *t* test compared to the WT value), but expression of the EAL mutant (E431A) resulted in a striking increase (*P* value of <0.05 by paired *t* test compared to the WT value) in the above phenotypes (Fig. 2A to C), suggesting that DcpA exhibits DGC enzymatic activity when PDE activity is abrogated. The concentration of *c*-di-GMP in the strain expressing the *dcpA* double mutant (E308A E431A) plasmid was not different from the plasmid-free strain (*P* value of 0.29 by paired *t* test compared to the WT value).

DcpA exhibits DGC activity in a heterologous host. Production of *c*-di-GMP is often controlled by a variety of upstream regulatory pathways, specific to the bacterial species in which they have evolved (9, 10). We hypothesized that *A. tumefaciens* might express regulatory proteins that modulate the DGC and PDE activity of DcpA. To examine enzymatic activity in a heterologous host lacking any *A. tumefaciens*-specific regulatory machinery, wild-type and mutant variants of DcpA were expressed from a multicopy plasmid in *Escherichia coli* DH5 α . *E. coli* DH5 α has a low basal level of *c*-di-GMP, and we have previously used it as an assay strain to show that several *A. tumefaciens* DGCs can elevate intracellular *c*-di-GMP levels significantly above the low endogenous *E. coli* background (50).

Unlike wild-type *A. tumefaciens*, expression of plasmid-borne wild-type *dcpA* in *E. coli* increased intracellular *c*-di-GMP concentrations by more than 2 orders of magnitude compared to the plasmid-less background (Fig. 2C, *P* value of <0.05 by paired *t* test). This increase in *c*-di-GMP was entirely dependent on the DGC activity of DcpA, as the GGDEF (E308A) mutation did not increase or decrease *c*-di-GMP levels compared to the wild type (*P* value of 0.26 by paired *t* test). This plasmid derivative is not generally dysfunctional, as it was able to successfully complement the *A. tumefaciens* $\Delta dcpA$ mutant for its presumptive PDE activity (Fig. 1A). The DGC activity of the EAL (E431A) mutant was similar to that of wild-type DcpA, indicating that the DGC activity of DcpA is functionally independent of PDE activity when the protein is expressed in *E. coli*. This is consistent with our finding in *A. tumefaciens* in which the PDE⁻ mutant exhibited strong DGC activity (Fig. 1A and 2C). Expression of the double mutant (E308A E431A) had no effect on *c*-di-GMP levels. Overall, these data suggest that DcpA acts as a potent DGC when expressed in *E. coli* and




FIG 2 Genetic analysis reveals DGC activity of DcpA. (A) Biofilms grown for 48 h on PVC coverslips were quantified as described in the legend to Fig. 1C. A wild-type strain with no plasmid inserted (-) is shown. The error bars show 1 standard deviation (SD). (B) Congo red colony phenotypes of *A. tumefaciens* strains after 48 h of growth at 28°C (vertically aligned with strain designations in panel A). (C) Quantification of intracellular levels of c-di-GMP in the indicated *A. tumefaciens* or *E. coli* strains. A DcpA variant containing catalytic site GGDEF→GGDAF mutation (DGC-) and a DcpA variant containing catalytic site EAL→AAL mutation (PDE-) were tested. c-di-GMP was measured by LC-MS/MS as described in Text S1 in the supplemental material. Values are results of two (*A. tumefaciens*) or three (*E. coli*) independent biological replicates consisting of three technical replicates each. The error bars show 1 SD.

that DcpA DGC activity is likely to be regulated by factors or conditions native to *A. tumefaciens*.

A putative pteridine reductase negatively regulates biofilm formation and UPP production in *A. tumefaciens*. We had identified additional candidate UPP and attachment regulators in our prior transposon mutant screen for UPP dysregulation (50) and hypothesized that some of these might consolidate into common control pathways. Of the four classes of candidate regulators, transposon mutations in *Atu1130* exhibited the highest level of biofilm formation when disrupted (50). As detailed below,

Atu1130 and *DcpA* are functionally linked in their control over UPP production and surface attachment in general.

The *Atu1130* gene is on the circular chromosome, and it is expressed divergently from an outer membrane protein homolog designated *aopB* (*Atu1131*). The 3' end of the *Atu1130* coding sequence overlaps by 4 bp with the downstream gene homologous to the *UvrC* UV repair exonuclease protein (*Atu1129*), suggesting that these genes are translationally coupled. The *Atu1130* gene encodes a 262-aa gene product that shares significant sequence similarity with pteridine reductase proteins, a subclass of the short-chain dehydrogenase/reductase protein family (53, 54). The annotated pteridine reductase domain extends from positions 14 to 247 and is the only recognized domain of the *Atu1130* protein. Due to these characteristics, *Atu1130* was renamed *PruA* (pteridine reductase regulator of UPP A). Pteridine reductases catalyze the NADPH-dependent reduction of metabolites derived from GTP, known as pterins, to their biologically active forms. The most well-known pterin-containing molecules are folates, while other pterin compounds, such as the molybdopterin cofactor, bi-pterins, and monapterins, function as enzymatic prosthetic groups that drive redox catalysis (55–58). The pteridine reductase family is characterized by a conserved YXXXK catalytic motif that is necessary for enzymatic function (53, 59, 60). *PruA* contains the canonical YXXXK motif (see Fig. S4A in the supplemental material) and exhibits predicted secondary and tertiary structural homology with well-characterized pteridine reductases such as PTR1 from *Leishmania donovani* (Fig. S4D).

An in-frame deletion of *pruA* that retains the potential translational coupling with *uvrC* results in an approximately fivefold elevation of biofilm formation compared to the wild type (Fig. 3A, *P* value of <0.05 by paired *t* test). As predicted by elevated biofilm levels, a *pruA* mutant also had slight, but statistically higher levels of c-di-GMP than the wild type did (see Fig. S3 in the supplemental material, *P* value of <0.05 by paired *t* test). The Δ *pruA* mutant also formed dark red colonies on Congo red-containing medium (Fig. 3B), indicative of elevated levels of cellulose and UPP. The elevated levels of biofilm formation and Congo red staining were returned to normal levels (Fig. 3A and B) by ectopic expression of a plasmid-borne copy of *pruA* (*P_{lac}-pruA*), confirming that the mutant phenotypes are not due to polarity on *uvrC*.

To observe UPP production directly, cells were stained using wheat germ agglutinin (WGA) conjugated to the Alexa Fluor 594 fluorescent label (af-WGA). WGA specifically binds to *N*-acetylglucosamine-containing polysaccharides and specifically labels the site of UPP production in *A. tumefaciens* (50, 61). UPP production is tightly dependent on surface attachment in wild-type *A. tumefaciens* (62), and little to no WGA staining was observed for planktonically grown cultures (Fig. 3C). In contrast, the Δ *pruA* mutant exhibited abundant UPP staining and high levels of cellular aggregation, also consistent with cellulose production (Fig. 3C). UPP staining was concentrated in the large cell aggregates, but it was also visible on single cells. As UPP production is normally not observed in planktonically grown cells (50, 62), synthesis of the adhesin is thus uncoupled from surface attachment in the Δ *pruA* mutant, consistent with other regulatory mutants identified in our initial screen such as *visN* and *visR* (50). The plasmid-borne *pruA* gene complements the mutant phenotypes back to wild-type levels. These observations suggest that *PruA* is an important regulatory player in the pathway controlling the *A. tumefaciens* motile-to-sessile transition.




FIG 3 Enzymatic activity of PruA required for control of attachment. (A) Biofilms grown on PVC coverslips for 48 h were quantified as described in the legend to Fig. 1C. A wild-type strain with no plasmid inserted (-) and the *pruA* mutant strain with no plasmid inserted (-) are indicated. The error bars show 1 SD. (B) Congo red colony phenotypes of the indicated *A. tumefaciens* strains. The bacteria were grown for 48 h at 28°C. (C) Unipolar polysaccharide (UPP) production (red) visualized by staining with Alexa Fluor 594-labeled wheat germ agglutinin (afWGA). Exponential-phase planktonic cultures were incubated with afWGA (10 μ g/ml) and spotted (1 μ l) onto 1% agarose pad. Bacteria were viewed at a magnification of $\times 100$ on a Nikon E800 epifluorescence microscope (excitation, 510 to 560 nm; emission, >610 nm). The images shown are overlays of phase-contrast and fluorescence microscopy images. The images were exposed for 40 and 400 ms for phase-contrast and fluorescence microscopy, respectively. IPTG (400 μ M) was added to each culture. Bars, 5 μ m.

PruA enzymatic activity required for function. To test whether the enzymatic activity of PruA was required for negative regulation of attachment phenotypes, a site-directed mutation (Y163A) that altered the tyrosine residue in the presumptive active site (YXXXXK) of PruA to an alanine was generated. In other systems, these mutations have been shown to abolish pteridine reductase activity but not affect protein stability (60). A plasmid expressing wild-type *pruA* can diminish biofilm formation and Congo red phenotypes in a $\Delta pruA$ mutant (Fig. 3A and B). In contrast, the PruA Y163A mutation abolished the ability of this plasmid to complement, exhibiting biofilm levels and Congo red staining indistinguishable from those of the mutant without the plasmid (Fig. 3A and B, *P* value of 0.34 by paired *t* test). The Y163A

mutation was also introduced into the native genomic context of *pruA* by allelic replacement, and this mutant was similar to the $\Delta pruA$ deletion strain with respect to all measured phenotypes, including biofilm formation (see Fig. S5 in the supplemental material) and Congo red staining (data not shown). PruA enzymatic activity thus appears to inhibit surface attachment processes, including UPP production in *A. tumefaciens*.

PruA orthologs from other bacteria can rescue the *A. tumefaciens* *pruA* mutant. PruA orthologs are observed in several related members of the *Rhizobiales* order and *Alphaproteobacteria* class, including *Sinorhizobium meliloti*, *Caulobacter crescentus*, *Ruegeria pomeroyi*, and *Brucella abortus*, with all homologs exhibiting approximately 40% amino acid identity or higher. Each of the PruA orthologs possesses a canonical YXXXXK motif (see Fig. S4A in the supplemental material), suggesting a conserved enzymatic function. When expressed from P_{lac} on a plasmid, all of these homologs drove the $\Delta pruA$ biofilm phenotype and Congo red staining toward wild-type levels (Fig. S4B and C). The closest *E. coli* homolog to PruA is known as FolM (26% identity to PruA), an experimentally validated pteridine reductase. FolM functions as a dihydropterin reductase, reducing dihydromonapterin (H_2 -MPt) to tetrahydromonapterin (H_4 -MPt) (58). Strikingly, ectopic expression of *folM* in *A. tumefaciens* also partially reverses the biofilm and Congo red phenotypes of the $\Delta pruA$ mutant (Fig. S4B and C).

PruA is required for production of a novel pterin. In order to evaluate the activity of PruA, we examined the intracellular pterin profiles in fractionated preparations from *A. tumefaciens* using high-performance liquid chromatography (HPLC) with fluorescence detection. All analyses were performed on oxidized extracts, as pterin derivatives in their oxidized state are strongly fluorescent. This technique is highly sensitive for oxidized pterin species, but its use precludes the determination of the reduction state of the pterin. This analysis showed the presence of three major pterin-containing peaks (Fig. 4A). The peak that eluted at 11.7 min corresponds to pterin (Fig. 4B), a major degradation product of tetrahydrofolate, commonly found in cell extracts (63). The peak at 3.8 min is likely a folate biosynthetic intermediate containing a phosphate group, and although this compound appeared to decrease in the cells lacking PruA, the significance of this is not yet clear. The peak eluting at 12.5 min had a characteristic pterin absorbance spectrum and was strikingly absent from the $\Delta pruA$ and *pruA* Y163A mutants but was present when the $\Delta pruA$ mutant was complemented with the P_{lac} -*pruA* plasmid.

Since the species eluting at 12.5 min did not match any known pterin based on retention time, the peak was collected and analyzed further by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The unknown pterin had a $(M+H)^+$ of 268 *m/z* and $(M-H)^-$ of 266 *m/z*, corresponding to a molecular mass of 267 Da, consistent with the addition of a methyl group to neopterin or monapterin, which differ only in stereochemistry at the 2' position (Fig. 4B). Collision-induced dissociation (CID) of the $(M-H)^-$ precursor ion gave rise to a pterin fragment at 162 *m/z*, indicating that the methyl group is not on the pterin portion of the molecule and must be present on the side chain to generate an O-methylated neopterin or monapterin derivative. FolM from *E. coli* reduces 7,8-dihydromonapterin (H_2 MPt) to 5,6,7,8-tetrahydromonapterin (H_4 MPt) but has no activity with 7,8-dihydroneopterin (58). Given the similarity of PruA and FolM, it seemed likely that the PruA substrate is 7,8-




FIG 4 PruA enzymatic activity required for pterin synthesis. (A) HPLC traces of pterin extracts from the indicated *A. tumefaciens* strains. Lyophilized cells were resuspended, and pterins were extracted, purified, and analyzed by HPLC as described in Materials and Methods. (B) Pterin chemical structures (ring positions shown).

dihydroneopterin and that the methylated pterin compound we identified in *A. tumefaciens* is a methylated neopterin rather than neopterin. We synthesized 6-methoxymethylpterin (lacking the full side chain of the monapterin) and analyzed the compound by LC-MS/MS. The MS/MS data obtained from this compound were very different from the data obtained from the unknown pterin isolated from *A. tumefaciens* (data not shown), indicating that the methyl group was not likely at the 1' position, and further analysis led us to propose O-methylation at the 2' position. We therefore synthesized 2'-O-methylmonapterin, and HPLC and LC-MS/MS analyses revealed that it had the same retention time and MS/MS spectrum as the *A. tumefaciens* pterin (Fig. S7B and S7C). The unknown oxidized pterin present in *A. tumefaciens* is therefore 2'-O-methylmonapterin.

A. tumefaciens PruA was purified as a hexahistidinyl-tagged PruA protein (His6-PruA) from *E. coli*. The purified protein was tested for enzymatic activity, monitoring oxidation of NADPH, and was found to reduce H₂MPt (specific activity, $0.726 \pm 0.039 \mu\text{mol min}^{-1} \text{mg}^{-1}$), but it had no activity with dihydro-

neopterin, dihydrofolate, or other oxidized pterins. Thus, PruA does function as predicted for a pteridine reductase. Taken together, our results indicate that PruA can generate H₄MPt from H₂HPt but that another cellular activity in *A. tumefaciens* must convert this to 2'-O-methyltetrahydromonapterin (2'-OMet-H₄MPt). One or both of these pterins regulate DcpA activity and attachment.

Regulatory connection between PruA and DcpA. In our initial transposon mutant screen (50), *pruA* and *dcpA* mutants exhibited similar phenotypes, and thus, we hypothesized that they might function together. To test the hypothesis that *pruA* and *dcpA* are part of the same regulatory pathway, plasmid-borne copies of either *pruA* or *dcpA* were introduced independently into the $\Delta dcpA$ and $\Delta pruA$ mutant backgrounds. Expressing *pruA* in a *dcpA* mutant did not change its phenotype compared to the untransformed *dcpA* mutant (data not shown). In contrast, expressing *dcpA* in a *pruA* background (deleted for cellulose [Cel⁻] to reduce excessive clumping) resulted in an approximately twofold increase above the already elevated biofilm phenotype of the $\Delta pruA$ mutant alone (Fig. 5A, P value of <0.05 by paired *t* test). This increased biofilm formation was accompanied by increased cell aggregation and elevated UPP staining (Fig. 5B) and an increase of more than 2 orders of magnitude in intracellular c-di-GMP concentrations compared to the $\Delta pruA$ strain (Fig. 5A, P value of <0.05 by paired *t* test). Introducing the *P_{lac}-dcpA* plasmid into the chromosomal *pruA* catalytic site mutant (Y163A) increased biofilm formation similar to that observed in the $\Delta pruA$ background (see Fig. S5 in the supplemental material). Thus, in contrast to the PDE activity of DcpA that predominates in wild-type *A. tumefaciens*, DcpA acts as a strong DGC in the absence of an enzymatically active copy of *pruA*, analogous to its activity when expressed in *E. coli*.

The plasmid carrying the GGDEF mutant allele (E308A) of *dcpA* was introduced into the $\Delta pruA$ background, and it did not stimulate elevated biofilm formation or increase c-di-GMP levels (Fig. 5A, P value of >0.05 by paired *t* test). The elevation of biofilm and c-di-GMP levels was still strongly stimulated by introduction of the plasmid-borne EAL mutant (E431A) of *dcpA* in the $\Delta pruA$ background, suggesting again that DcpA DGC activity is functionally independent of an enzymatically active PDE domain. Plasmid-borne expression of the GGDEF-EAL double mutant (E308A E431A) had no effect on the $\Delta pruA$ phenotypes. It seemed likely that the $\Delta pruA$ phenotypes might be DcpA dependent, and a $\Delta pruA \Delta dcpA$ double mutant was found to diminish biofilm levels below that of the $\Delta pruA$ single mutant to that of the $\Delta dcpA$ mutant (Fig. 5C, P value of <0.05 by paired *t* test). Thus, the *dcpA* mutation is epistatic to *pruA* and is downstream in the regulatory pathway. The very strong *pruA* mutant phenotypes are also likely due to the combined effect of a decrease in DcpA PDE activity and sustained or stimulated DcpA DGC activity.

PruA-dependent regulation of DcpA requires a putative pterin-binding protein. Despite our observations for PruA and DcpA, it was not clear how PruA-dependent pterin production could control DcpA. As mentioned above, *dcpA* is immediately preceded by *Atu3496* in a putative operon (Fig. 1A) (50). In fact, several transposon insertion mutations were identified in the *Atu3496* gene during the initial mutant screen. *Atu3496* is a 169-aa protein, the majority of which (positions 34 to 172) shows modest but significant similarity to an oxidoreductase molybdopterin-binding domain (pfam00174, BLAST E value of 3.14×10^{-8} , spe-




FIG 5 Regulatory connections between PruA and DcpA. (A) Biofilms grown for 48 h on PVC coverslips (gray bars) were quantified as described in the legend to Fig. 1C. The error bars show 1 SD. c-di-GMP levels were also quantified (black bars). Strains were grown to stationary phase, nucleotides were extracted, and c-di-GMP was measured as described in Materials and Methods. A DcpA variant with catalytic site GGDEF→GGDAF mutation (DGC-), DcpA variant containing catalytic site EAL→AAL mutation (PDE-), and mutant with no plasmid inserted (-) were used. The Δcel background was utilized to reduce excess clumping. Values are results of three (biofilm) or two (c-di-GMP) independent biological replicates consisting of three technical replicates each. The error bars show 1 SD. (B) UPP production visualized by staining with afWGA, as described in the legend to Fig. 3C. IPTG (400 μ M) was added to each culture. Bars, 5 μ m. (C) Adherent biomass grown for 48 h was quantified as described above for panel A, with IPTG omitted.

cific match to *E. coli* YedY, HHPred E value of 1.5×10^{-31}). These domains are generally utilized for molybdopterin cofactor binding, through conjugation at a conserved cysteine residue that is required for the proper function of redox enzymes such as sulfite oxidases (55). This cysteine residue is absent in the *Atu3496* gene, and several conserved residues are divergent, suggesting that it may not bind molybdopterin specifically. There are several homologous proteins in other *Alphaproteobacteria* that also lack this

conserved cysteine (see Fig. S6A in the supplemental material). We hypothesized that this domain in *Atu3496* might instead provide response to the pterin derivative produced by PruA. We tentatively designated the gene *pruR* (pteridine reductase regulator of UPP receptor).

An in-frame deletion in *pruR* was generated, with care taken not to disrupt the start site or ribosome-binding site of *dcpA*. Deletion of *pruR* resulted in an approximately 3.5-fold increase in biofilm formation compared to the wild type (Fig. 6A, P value of <0.05 by paired *t* test), increased af-WGA labeling (Fig. 6B), and elevated Congo red staining (data not shown), indicating that PruR negatively regulates attachment processes in *A. tumefaciens*. Ectopic expression of a plasmid-borne *pruR* gene reduced the biofilm levels of a $\Delta pr u R$ mutant only slightly (P value of <0.05 by paired *t* test), whereas providing expression of a plasmid with both *pruR* and *dcpA* in their normal tandem configuration reduced biofilm formation very strongly to below wild-type levels (Fig. 6A, P value of <0.05 by paired *t* test). The strong suppressive effect on the *pruR* phenotype observed with the *P_{lac}-pruR-dcpA* tandem expression plasmid was abolished in a $\Delta pr u A \Delta pr u R$ double mutant (see Fig. S6B in the supplemental material). The requirement for this dual-gene plasmid suggests a strong *cis* association and perhaps a cotranslational interaction. We are confident that the $\Delta pr u R$ mutation does not disrupt the downstream *dcpA*, and this is further supported in that providing a plasmid-borne *dcpA* alone in this mutant stimulates biofilm formation rather than returning the elevated levels of *pruR* closer to the wild-type levels, the opposite effect one would predict for correcting a *dcpA* deficiency (see below). These data suggest that *pruR* and *pruA* might act in concert to regulate DcpA activity

PruR is required to maintain the dominant PDE activity of DcpA. We predicted that PruR would regulate the dual enzymatic activities of DcpA, and thus, a switch in DcpA enzymatic activity might be observed in a *pruR* mutant similar to *pruA* mutants. To test this, the *P_{lac}-dcpA* plasmid was expressed in the *A. tumefaciens* $\Delta pr u R$ mutant (also mutated for the cellulose biosynthetic genes to prevent aggregation) and assayed for biofilm formation. As observed before, a $\Delta pr u R$ mutant exhibited higher biofilm levels than the wild type did (Fig. 6C, P value of <0.05 by paired *t* test). Expression of the plasmid-borne *dcpA* increased biofilm formation approximately fourfold above the $\Delta pr u R$ mutant (Fig. 6C, P value of <0.05 by paired *t* test). The *dcpA*-mediated increase in biofilm formation was abrogated in the DcpA (E308A) GGDEF catalytic site mutant (Fig. 6C). However, plasmid-borne expression of the DcpA (E431A) EAL catalytic site mutant stimulated biofilm formation equivalent to the wild-type gene, indicating again that the DGC activity was retained in the PDE mutant (Fig. 6C). Furthermore, introduction of the *P_{lac}-pruR-dcpA* plasmid into *E. coli* did not increase c-di-GMP levels, in contrast to the dramatic increases observed with the *P_{lac}-dcpA* plasmid (Fig. 6D). Overall, these data suggest that PruR, like PruA, controls the enzymatic activity of DcpA. PruR and PruA by themselves are both necessary but not sufficient for proper regulation of DcpA, as DcpA functions as a PDE only in the presence of both PruA and PruR.

DISCUSSION

In this study, we confirm and expand our initial report (50) on *dcpA* (*Atu3495*) in *A. tumefaciens*. We demonstrate that DcpA PDE activity, and specifically the EAL domain, is essential for the




FIG 6 PruR negatively regulates biofilm formation. (A) Biofilms grown for 48 h on PVC coverslips were quantified as described in the legend to Fig. 1C. A $\Delta pruR$ mutant with no plasmid inserted is indicated (-). The error bars show 1 SD. (B) UPP production visualized by staining with afWGA, as described in the legend to Fig. 3C. Bars, 5 μ m. (C) Adherent biomass grown for 48 h was quantified as described above for panel A, with IPTG omitted. The Δcel background was utilized to reduce excess clumping. (D) Quantification of c-di-GMP levels in the indicated *E. coli* strains. The *E. coli* strains were grown to late exponential phase, and nucleotides were extracted and quantified as described in Text S1 in the supplemental material. Values are results of two independent biological replicates each with three technical replicates. The error bars show 1 SD.

negative regulation of UPP adhesin production, cellulose synthesis, and biofilm formation, through its impact on c-di-GMP levels that regulate production of these polysaccharides and other aspects of the motile-to-sessile transition. We also describe, through the use of site-specific mutagenesis, the ability of DcpA to exhibit *in vivo* DGC activity, and that the DGC and PDE activities are independent of each other. Our findings reveal that the DcpA activity is controlled through a novel, pterin-dependent regulatory mechanism.

A dual-function diguanylate cyclase-phosphodiesterase in *A. tumefaciens*. Demonstration of both DGC and PDE enzymatic activities from the same protein is not typical, as a large percentage of proteins with both GGDEF and EAL domains exhibit only one of the two functionalities (30, 31). For those examples of proteins with both activities, the overarching regulatory networks that control them are often unclear, and *in vivo* data are scarce. We find here that the enzymatic activity of PruA (Atu1130), is responsible for the negative control of attachment phenotypes through the PDE activity of DcpA, as manifested through the function of the PruR protein (Atu3496).

There are a limited number of well-studied dual-function proteins with both PDE and DGC activity. Arguably the best-known DGC-PDE protein is ScrC from *Vibrio parahaemolyticus*, which positively regulates swarming and negatively regulates capsular polysaccharide (CPS) production (37). ScrC is a transmembrane protein with a periplasmic domain, and its PDE activity requires ScrB, a periplasmic solute-binding protein homolog, and ScrA, homologous to pyridoxal-dependent-enzymes (36). ScrA generates an extracellular signal (S-signal), and together with ScrB, it promotes the PDE activity of ScrC. In the absence of ScrA and ScrB, the DGC activity of ScrC dominates. Thus, for both ScrC and DcpA, c-di-GMP turnover is controlled by two upstream regulatory partners (ScrA and ScrB in *V. parahaemolyticus* and PruA and PruR in *A. tumefaciens*). In each case, one regulatory partner is required to synthesize a small molecule, S-signal by ScrA and a pterin by PruA. Another recently described dual-function DGC-PDE is BphG1 of *Rhodobacter sphaeroides*, consisting of an N-terminal photosensory module coupled to a C-terminal output module containing GGDEF and EAL domains (34). Purified full-length BphG1 demonstrates PDE activity *in vitro*, but ablation of the EAL domain results in strong DGC activity. It remains unclear whether similar cleavage of the EAL domain occurs *in vivo*, and BphG1 DGC activity has not been observed in a native background. In contrast, for DcpA, we observe both DGC and PDE activity *in vivo*, and these activities have clear cellular phenotypes linked to DcpA output.

Pterin synthesis and DcpA regulation. It is now clear that the enzymatic activity of PruA is required for DcpA PDE activity and that PruA directs the formation of 5,6,7,8-tetrahydromonapterin (H_4 Mpt). Extracts from *A. tumefaciens* reveal PruA-dependent production of the novel monapterin 2'-OMet- H_4 Mpt, and thus, the H_4 Mpt that is the direct product of PruA activity is likely to be a substrate for methylation by an as-yet-unidentified enzyme (Fig. 7; see Fig. S7A in the supplemental material). Since pterins readily undergo oxidation and degradation upon isolation from cells, we do not observe the tetrahydro product in *A. tumefaciens* extracts but instead observe the oxidized form of the pterin, 2'-OMet-Mpt (Fig. 4A).

In well-studied systems, monapterin biosynthesis branches from folate metabolism (58), and we predict that this is similar in




FIG 7 Model of pterin-dependent DcpA regulation. A tentative model for DcpA regulation is shown. The model is based on the findings reported here, with details provided in the text. Solid black arrows are enzymatic reactions, dashed arrows are regulatory interactions, and the squiggly arrow is a speculative environmental influence on the putative PruR-pterin (Pt) complex. Red text indicates essential genes in *A. tumefaciens*. IM, inner membrane; OM, outer membrane; GTs, glycosyl transferases; MoPT, molybdopterin; P-ase, phosphatase.

A. tumefaciens (Fig. 7). Both folate and monapterin are derived from GTP through the common intermediate 2,3-dihydro-neopterin triphosphate (H₂NPT-P₃) by a GTP cyclohydrolase, encoded by *folE* in *E. coli*, and homologous to *Atu1749* in *A. tumefaciens* (64). The well-studied molybdopterin cofactor is synthesized via a different pathway that also utilizes GTP as an intermediate (65). Analogous to the *E. coli* pathway for monapterin biosynthesis, the likely pathway in *A. tumefaciens* would share several key enzymes with folate biosynthesis, acting on either a neopterin for folate or a monapterin (Fig. 7). H₂MPt formed by this pathway could then be reduced to H₄-MPt. In *A. tumefaciens*, all of the enzymes predicted to be required prior to the PruA-dependent reaction are essential for growth (Fig. 7, red *Atu* genes), even in rich medium (66), thus explaining why no other transposon mutants with *pruA*-type phenotypes were obtained for this pathway. This also suggests that in *A. tumefaciens*, folate is essential for growth, but monapterin is not.

PruR-pterin interactions. PruR is required for the PruA-dependent control of the enzymatic activity of DcpA by promoting its PDE activity. Although PruR is annotated as a molybdopterin-binding protein, it is degenerate and most importantly missing the key cysteine ligand for molybdopterin (67). As it is clear that PruA drives H₄MPt synthesis, the simplest model is that PruR can respond to a monapterin. Cells with active PruA

produce 2'-OMet-H₄MPt, presumably derived from methylation of H₄MPt, but no mutants with the *pruA* phenotype were obtained for any annotated methyltransferase. Therefore, it is possible that H₄MPt produced by PruA is in fact the active molecule for PruR-dependent control or that the methyltransferase gene is another essential gene.

A relatively simple model is that a PruA-dependent pterin interacts with PruR, perhaps by forming a complex. Such a PruR-pterin complex could directly or indirectly interact with DcpA to promote its PDE activity (Fig. 7). More-complex models might also be envisioned, such as a mechanism by which the monapterin species limits the action of an inhibitor of PruR. Such a mechanism would be consistent with the observation that PruR effectively switches DcpA from its DGC dominant state in *E. coli*, a host that does not produce the novel monapterin we have detected in *A. tumefaciens*.

Since the PDE activity predominates under standard culture conditions in wild-type *A. tumefaciens*, it is possible that the PDE domain, when enzymatically active, exerts a negative regulation on the DGC domain. In ScrC of *V. parahaemolyticus*, the GGDEF catalytic motif is required for its PDE activity (38), but in contrast, the DcpA PDE activity appears to remain functional in GGDEF catalytic site mutants. Alternatively, both domains may be active, but the PDE activity greatly exceeds the DGC activity, leading to

predominant c-di-GMP inactivation, and thus inhibition of attachment functions such as UPP and cellulose.

Pterin-dependent regulation. It is not obvious why or how monapterins would control DcpA activity. The simplest explanation is that the intracellular concentration of a specific monapterin(s) directly modulates DcpA, probably through interactions with PruR. The monapterin pathway derives from GTP and folate synthesis, and thus, the concentration of these compounds could reflect the overall levels of GTP. Alternatively, the monapterin could function as several other GTP derivatives such as c-di-GMP and ppGpp (10, 68, 69) directly as a second messenger.

It is also plausible that monapterin might function as a sensor of the cytoplasmic redox state through association with PruR and perhaps DcpA. PAS domains containing heme cofactors have been shown to modulate PDE activity through reversible binding of oxygen (70, 71). Redox sensing by flavin cofactors can regulate the enzymatic activity of a DGC protein in *Acetobacter xylinum* (72), and it is possible that pterins could operate in a similar capacity (58). Reduced pterins are known to act as robust antioxidants in mammalian cells (73), and high levels of oxidized neopterin are associated with increased concentrations of reactive oxygen species (ROS) (74). Additionally, several pterins are involved in regulating a redox-sensitive transcription factor in mammalian cells (75, 76). Oxygen availability has been postulated to play an important role during biofilm formation in *A. tumefaciens* (43), and biofilms often generate oxygen gradients (77). Sensing oxygen or changes in intracellular redox balance during the transition from the motile to sessile state could be mediated in part through monapterin control of DcpA.

The mechanism by which PruR directs the monapterin-mediated control of DcpA activity also remains to be established. An intimate relationship between PruR and DcpA is suggested by their transcriptional linkage within the same operon and the observation that their coexpression appears to potentiate the PruR-dependent stimulation of PDE activity. Regulation of DcpA via PruR could occur via several possible mechanisms, including direct binding and occlusion of the DGC domain, direct promotion of the PDE domain, or both, as well as control of proper DcpA subcellular localization. The interaction between PruR and DcpA may be through formation of a stable complex between the two proteins and a monapterin prosthetic group. Other more-complex possibilities are also possible. For example, PruR might have an as-yet-undiscovered enzymatic capability that is active only in the presence of a specific pterin cofactor, as with pterin-dependent enzymes, including phenylalanine hydroxylase (58). The enzymatic activity of PruR could directly modify DcpA or synthesize another small molecule that in turn controls DcpA activity.

Ultimately, a more detailed understanding of the PruA-PruR-DcpA pathway will result from biochemical analysis of the different regulatory components and investigation into the cellular context of its activity. Our current findings provide the first example of pterins participating in a prokaryotic signaling cascade, in this case regulating surface attachment through adhesin production in *A. tumefaciens*. Pterins are produced by diverse bacteria, and thus, it is possible that similar pterin-dependent control is widespread.

MATERIALS AND METHODS

Reagents, media, strains, and growth conditions. All strains and plasmids and all oligonucleotides used in this study are provided in Tables S1 and S2 in the supplemental material, respectively. The design and verifi-

cation of plasmids and engineered genetic derivatives, including site-specific mutagenesis, deletions, and allelic exchanges were performed as described in previous publications (45, 50) with specific details included in Text S1 in the supplemental material.

Biofilm analysis and UPP adhesin assays. Biofilms of *A. tumefaciens* derivatives were cultivated in minimal medium on polyvinyl chloride (PVC) coverslips in 12-well plates, and adherent biomass was measured using crystal violet as in our prior publications (45, 78). Cells producing the UPP adhesin were examined using epifluorescence microscopy and the fluorescently labeled lectin af-WGA as described previously (50).

c-di-GMP measurements. Extracts were prepared from cultures of *A. tumefaciens* and *E. coli* derivatives and analyzed using LC-MS/MS on a Quattro Premier XE mass spectrometer (Waters Corporation) coupled with an Acquity ultraperformance LC system (Waters Corporation) as described in a previous publication (50).

Extraction and analysis of pterins from *A. tumefaciens*. Whole-cell extracts prepared from late-exponential-phase cultures of *A. tumefaciens* were prepared, and pterins were enriched using cation exchange chromatography. These preparations were analyzed using HPLC on a reverse-phase C₁₈ column with fluorescence detection as previously described (79) and provided in Text S1 in the supplemental material in more detail.

Purification and enzymatic assay of His6-PruA. An N-terminal hexahistidiny-tagged PruA (His6-PruA) derivative was expressed in *E. coli* and affinity purified. This preparation was tested for enzymatic activity using an H₂MpT substrate prepared by reduction of monapterin and a dihydrofolate substrate using an assay monitoring consumption of NADPH in the reaction spectrophotometrically using extinction coefficients for the NADPH-pterin oxidation-reduction pair.

Additional details on the materials and methods used in this study are provided in Text S1 in the supplemental material.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.00156-15/-/DCSupplemental>.

Figure S1, PDF file, 0.1 MB.
Figure S2, PDF file, 0.1 MB.
Figure S3, PDF file, 0.02 MB.
Figure S4, PDF file, 0.3 MB.
Figure S5, PDF file, 0.01 MB.
Figure S6, PDF file, 0.3 MB.
Figure S7, PDF file, 0.1 MB.
Table S1, PDF file, 0.1 MB.
Table S2, PDF file, 0.1 MB.
Text S1, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

This project was supported by National Institutes of Health (NIH) grant GM080546 (C.F.) and National Science Foundation grants MCB-1253684 (C.M.W.) and MCB-0722787 (R.H.W.). N.F. was funded by the Indiana University Genetics, Molecular and Cellular Sciences NIH training grant T32-GM007757.

We thank Jason Heindl for helping to edit the manuscript and the MSU Mass Spectrometry Facility for assistance with the mass spectrometry measurements.

REFERENCES

- Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. *Nat Rev Microbiol* 2:95–108. <http://dx.doi.org/10.1038/nrmicro821>.
- Danhorn T, Fuqua C. 2007. Biofilm formation by plant-associated bacteria. *Annu Rev Microbiol* 61:401–422. <http://dx.doi.org/10.1146/annurev.micro.61.080706.093316>.
- Flemming HC, Wingender J. 2010. The biofilm matrix. *Nat Rev Microbiol* 8:623–633. <http://dx.doi.org/10.1038/nrmicro2415>.
- Mah TF, O'Toole GA. 2001. Mechanisms of biofilm resistance to antimicrobial agents. *Trends Microbiol* 9:34–39. [http://dx.doi.org/10.1016/S0966-842X\(00\)01913-2](http://dx.doi.org/10.1016/S0966-842X(00)01913-2).

5. Anderl JN, Franklin MJ, Stewart PS. 2000. Role of antibiotic penetration limitation in *Klebsiella pneumoniae* biofilm resistance to ampicillin and ciprofloxacin. *Antimicrob Agents Chemother* 44:1818–1824. <http://dx.doi.org/10.1128/AAC.44.7.1818-1824.2000>.
6. McKew BA, Taylor JD, McGenity TJ, Underwood GJ. 2011. Resistance and resilience of benthic biofilm communities from a temperate salt marsh to desiccation and rewetting. *ISME J* 5:30–41. <http://dx.doi.org/10.1038/ismej.2010.91>.
7. Houry A, Gohar M, Deschamps J, Tischenko E, Aymerich S, Gruss A, Briandet R. 2012. Bacterial swimmers that infiltrate and take over the biofilm matrix. *Proc Natl Acad Sci U S A* 109:13088–13093. <http://dx.doi.org/10.1073/pnas.1200791109>.
8. del Pozo JL, Patel R. 2007. The challenge of treating biofilm-associated bacterial infections. *Clin Pharmacol Ther* 82:204–209. <http://dx.doi.org/10.1038/sj.clpt.6100247>.
9. Hengge R. 2009. Principles of c-di-GMP signalling in bacteria. *Nat Rev Microbiol* 7:263–273. <http://dx.doi.org/10.1038/nrmicro2109>.
10. Römling U, Galperin MY, Gomelsky M. 2013. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger. *Microbiol Mol Biol Rev* 77:1–52. <http://dx.doi.org/10.1128/MMBR.00043-12>.
11. Ross P, Weinhouse H, Aloni Y, Michaeli D, Weinberger-Ohana P, Mayer R, Braun S, de Vroom E, van der Marel GA, van Boom JH, Benziman M. 1987. Regulation of cellulose synthesis in *Acetobacter xylinum* by cyclic diguanylic acid. *Nature* 325:279–281. <http://dx.doi.org/10.1038/325279a0>.
12. Pérez-Mendoza D, Coulthurst SJ, Humphris S, Campbell E, Welch M, Toth IK, Salmond GP. 2011. A multi-repeat adhesin of the phytopathogen, *Pectobacterium atrosepticum*, is secreted by a type I pathway and is subject to complex regulation involving a non-canonical diguanylate cyclase. *Mol Microbiol* 82:719–733. <http://dx.doi.org/10.1111/j.1365-2958.2011.07849.x>.
13. Amikam D, Benziman M. 1989. Cyclic diguanylic acid and cellulose synthesis in *Agrobacterium tumefaciens*. *J Bacteriol* 171:6649–6655.
14. Lee HS, Gu F, Ching SM, Lam Y, Chua KL. 2010. CdpA is a *Burkholderia pseudomallei* cyclic di-GMP phosphodiesterase involved in autoaggregation, flagellum synthesis, motility, biofilm formation, cell invasion, and cytotoxicity. *Infect Immun* 78:1832–1840. <http://dx.doi.org/10.1128/IAI.00446-09>.
15. Steiner S, Lori C, Boehm A, Jenal U. 2013. Allosteric activation of exopolysaccharide synthesis through cyclic di-GMP-stimulated protein-protein interaction. *EMBO J* 32:354–368. <http://dx.doi.org/10.1038/emboj.2012.315>.
16. Tuckerman JR, Gonzalez G, Sousa EHS, Wan X, Saito JA, Alam M, Gilles-Gonzales M-A. 2009. An oxygen-sensing diguanylate cyclase and phosphodiesterase couple for c-di-GMP control. *Biochemistry* 48:9764–9774. <http://dx.doi.org/10.1021/bi901409g>.
17. Boehm A, Kaiser M, Li H, Spangler C, Kasper CA, Ackermann M, Kaever V, Sourjik V, Roth V, Jenal U. 2010. Second messenger-mediated adjustment of bacterial swimming velocity. *Cell* 141:107–116. <http://dx.doi.org/10.1016/j.cell.2010.01.018>.
18. Bobrov AG, Kirillina O, Ryjenkov DA, Waters CM, Price PA, Fetherston JD, Mack D, Goldman WE, Gomelsky M, Perry RD. 2011. Systematic analysis of cyclic di-GMP signalling enzymes and their role in biofilm formation and virulence in *Yersinia pestis*. *Mol Microbiol* 79:533–551. <http://dx.doi.org/10.1111/j.1365-2958.2010.07470.x>.
19. Pratt JT, Tamayo R, Tischler AD, Camilli A. 2007. PilZ domain proteins bind cyclic diguanylate and regulate diverse processes in *Vibrio cholerae*. *J Biol Chem* 282:12860–12870. <http://dx.doi.org/10.1074/jbc.M611593200>.
20. Curtis PD, Brun YV. 2010. Getting in the loop: regulation of development in *Caulobacter crescentum*. *Microbiol Mol Biol Rev* 74:13–41. <http://dx.doi.org/10.1128/MMBR.00040-09>.
21. Paul R, Weiser S, Amiot NC, Chan C, Schirmer T, Giese B, Jenal U. 2004. Cell cycle-dependent dynamic localization of a bacterial response regulator with a novel di-guanylate cyclase output domain. *Genes Dev* 18:715–727. <http://dx.doi.org/10.1101/gad.289504>.
22. Newell PD, Boyd CD, Sondermann H, O'Toole GA. 2011. A c-di-GMP effector system controls cell adhesion by inside-out signaling and surface protein cleavage. *PLoS Biol* 9:e1000587. <http://dx.doi.org/10.1371/journal.pbio.1000587>.
23. Chan C, Paul R, Samoray D, Amiot NC, Giese B, Jenal U, Schirmer T. 2004. Structural basis of activity and allosteric control of diguanylate cyclase. *Proc Natl Acad Sci U S A* 101:17084–17089. <http://dx.doi.org/10.1073/pnas.0406134101>.
24. Sudarsan N, Lee ER, Weinberg Z, Moy RH, Kim JN, Link KH, Breaker RR. 2008. Riboswitches in eubacteria sense the second messenger cyclic di-GMP. *Science* 321:411–413. <http://dx.doi.org/10.1126/science.1159519>.
25. Shikuma NJ, Fong JC, Yildiz FH. 2012. Cellular levels and binding of c-di-GMP control subcellular localization and activity of the *Vibrio cholerae* transcriptional regulator VpsT. *PLoS Pathog* 8:e1002719. <http://dx.doi.org/10.1371/journal.ppat.1002719>.
26. Simm R, Morr M, Kader A, Nimtz M, Römling U. 2004. GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. *Mol Microbiol* 53:1123–1134. <http://dx.doi.org/10.1111/j.1365-2958.2004.04206.x>.
27. Rao F, Yang Y, Qi Y, Liang ZX. 2008. Catalytic mechanism of cyclic di-GMP-specific phosphodiesterase: a study of the EAL domain-containing RocR from *Pseudomonas aeruginosa*. *J Bacteriol* 190:3622–3631. <http://dx.doi.org/10.1128/JB.00165-08>.
28. Schmidt AJ, Ryjenkov DA, Gomelsky M. 2005. The ubiquitous protein domain EAL is a cyclic diguanylate-specific phosphodiesterase: enzymatically active and inactive EAL domains. *J Bacteriol* 187:4774–4781. <http://dx.doi.org/10.1128/JB.187.14.4774-4781.2005>.
29. Ryan RP, Fouhy Y, Lucey JF, Crossman LC, Spiro S, He YW, Zhang LH, Heeb S, Cámara M, Williams P, Dow JM. 2006. Cell-cell signaling in *Xanthomonas campestris* involves an HD-GYP domain protein that functions in cyclic di-GMP turnover. *Proc Natl Acad Sci U S A* 103:6712–6717. <http://dx.doi.org/10.1073/pnas.0600345103>.
30. Christen M, Christen B, Folcher M, Schauerte A, Jenal U. 2005. Identification and characterization of a cyclic di-GMP-specific phosphodiesterase and its allosteric control by GTP. *J Biol Chem* 280:30829–30837. <http://dx.doi.org/10.1074/jbc.M504429200>.
31. Tal R, Wong HC, Calhoon R, Gelfand D, Fear AL, Volman G, Mayer R, Ross P, Amikam D, Weinhouse H, Cohen A, Sapir S, Ohana P, Benziman M. 1998. Three *cdg* operons control cellular turnover of cyclic di-GMP in *Acetobacter xylinum*: genetic organization and occurrence of conserved domains in isoenzymes. *J Bacteriol* 180:4416–4425.
32. Ferreira RB, Chodur DM, Antunes LC, Trimble MJ, McCarter LL. 2012. Output targets and transcriptional regulation by a cyclic dimeric GMP-responsive circuit in the *Vibrio parahaemolyticus* Scr network. *J Bacteriol* 194:914–924. <http://dx.doi.org/10.1128/JB.05807-11>.
33. Liu N, Xu Y, Hossain S, Huang N, Coursolle D, Gralnick JA, Boon EM. 2012. Nitric oxide regulation of cyclic di-GMP synthesis and hydrolysis in *Shewanella woodyi*. *Biochemistry* 51:2087–2099. <http://dx.doi.org/10.1021/bi201753f>.
34. Tarutina M, Ryjenkov DA, Gomelsky M. 2006. An unorthodox bacteriophytochrome from *Rhodobacter sphaeroides* involved in turnover of the second messenger c-di-GMP. *J Biol Chem* 281:34751–34758. <http://dx.doi.org/10.1074/jbc.M604819200>.
35. Bharati BK, Sharma IM, Kasetty S, Kumar M, Mukherjee R, Chatterji D. 2012. A full-length bifunctional protein involved in c-di-GMP turnover is required for long-term survival under nutrient starvation in *Mycobacterium smegmatis*. *Microbiology* 158:1415–1427. <http://dx.doi.org/10.1099/mic.0.053892-0>.
36. Trimble MJ, McCarter LL. 2011. Bis-(3'-5')-cyclic dimeric GMP-linked quorum sensing controls swarming in *Vibrio parahaemolyticus*. *Proc Natl Acad Sci U S A* 108:18079–18084. <http://dx.doi.org/10.1073/pnas.1113790108>.
37. Boles BR, McCarter LL. 2002. *Vibrio parahaemolyticus* *scrABC*, a novel operon affecting swarming and capsular polysaccharide regulation. *J Bacteriol* 184:5946–5954. <http://dx.doi.org/10.1128/JB.184.21.5946-5954.2002>.
38. Ferreira RB, Antunes LC, Greenberg EP, McCarter LL. 2008. *Vibrio parahaemolyticus* ScrC modulates cyclic dimeric GMP regulation of gene expression relevant to growth on surfaces. *J Bacteriol* 190:851–860. <http://dx.doi.org/10.1128/JB.01462-07>.
39. Van Larebeke N, Engler G, Holsters M, Van den Elsacker S, Zaenen I, Schilperoort RA, Schell J. 1974. Large plasmid in *Agrobacterium tumefaciens* essential for crown gall-inducing ability. *Nature* 252:169–170. <http://dx.doi.org/10.1038/252169a0>.
40. Watson B, Currier TC, Gordon MP, Chilton MD, Nester EW. 1975. Plasmid required for virulence of *Agrobacterium tumefaciens*. *J Bacteriol* 123:255–264.
41. Escobar MA, Dandekar AM. 2003. *Agrobacterium tumefaciens* as an agent

- of disease. *Trends Plant Sci* 8:380–386. [http://dx.doi.org/10.1016/S1360-1385\(03\)00162-6](http://dx.doi.org/10.1016/S1360-1385(03)00162-6).
42. Abarca-Grau AM, Penyalver R, López MM, Marco-Noales E. 2011. Pathogenic and non-pathogenic *Agrobacterium tumefaciens*, *A. rhizogenes* and *A. vitis* strains form biofilms on abiotic as well as on root surfaces. *Plant Pathol* 60:416–425. <http://dx.doi.org/10.1111/j.1365-3059.2010.02385.x>.
 43. Ramey BE, Matthyse AG, Fuqua C. 2004. The FNR-type transcriptional regulator SinR controls maturation of *Agrobacterium tumefaciens* biofilms. *Mol Microbiol* 52:1495–1511. <http://dx.doi.org/10.1111/j.1365-2958.2004.04079.x>.
 44. Tomlinson AD, Fuqua C. 2009. Mechanisms and regulation of polar surface attachment in *Agrobacterium tumefaciens*. *Curr Opin Microbiol* 12:708–714. <http://dx.doi.org/10.1016/j.mib.2009.09.014>.
 45. Xu J, Kim J, Danhorn T, Merritt PM, Fuqua C. 2012. Phosphorus limitation increases attachment in *Agrobacterium tumefaciens* and reveals a conditional functional redundancy in adhesin biosynthesis. *Res Microbiol* 163:674–684. <http://dx.doi.org/10.1016/j.resmic.2012.10.013>.
 46. Matthyse AG, Holmes KV, Gurlitz RH. 1981. Elaboration of cellulose fibrils by *Agrobacterium tumefaciens* during attachment to carrot cells. *J Bacteriol* 145:583–595.
 47. Matthyse AG, Marry M, Krall L, Kaye M, Ramey BE, Fuqua C, White AR. 2005. The effect of cellulose overproduction on binding and biofilm formation on roots by *Agrobacterium tumefaciens*. *Mol Plant Microbe Interact* 18:1002–1010. <http://dx.doi.org/10.1094/MPMI-18-1002>.
 48. Heindl JE, Wang Y, Heckel BC, Mohari B, Feirer N, Fuqua C. 2014. Mechanisms and regulation of surface interactions and biofilm formation in *Agrobacterium*. *Front Plant Sci* 5:176. <http://dx.doi.org/10.3389/fpls.2014.00176>.
 49. Barnhart DM, Su S, Baccaro BE, Banta LM, Farrand SK. 2013. CelR, an ortholog of the diguanylate cyclase PleD of *Caulobacter*, regulates cellulose synthesis in *Agrobacterium tumefaciens*. *Appl Environ Microbiol* 79:7188–7202. <http://dx.doi.org/10.1128/AEM.02148-13>.
 50. Xu J, Kim J, Koestler BJ, Choi JH, Waters CM, Fuqua C. 2013. Genetic analysis of *Agrobacterium tumefaciens* unipolar polysaccharide production reveals complex integrated control of the motile-to-sessile switch. *Mol Microbiol* 89:929–948. <http://dx.doi.org/10.1111/mmi.12321>.
 51. Schirmer T, Jenal U. 2009. Structural and mechanistic determinants of c-di-GMP signalling. *Nat Rev Microbiol* 7:724–735. <http://dx.doi.org/10.1038/nrmicro2203>.
 52. Pérez-Mendoza D, Aragón IM, Prada-Ramírez HA, Romero-Jiménez L, Ramos C, Gallegos MT, Sanjuán J. 2014. Responses to elevated c-di-GMP levels in mutualistic and pathogenic plant-interacting bacteria. *PLoS One* 9:e91645. <http://dx.doi.org/10.1371/journal.pone.0091645>.
 53. Jörnvall H, Persson B, Krook M, Atrian S, González-Duarte R, Jeffery J, Ghosh D. 1995. Short-chain dehydrogenases/reductases (SDR). *Biochemistry* 34:6003–6013. <http://dx.doi.org/10.1021/bi00018a001>.
 54. Oppermann U, Filling C, Hult M, Shafqat N, Wu X, Lindh M, Shafqat J, Nordling E, Kallberg Y, Persson B, Jörnvall H. 2003. Short-chain dehydrogenases/reductases (SDR): the 2002 update. *Chem Biol Interact* 143-144:247–253. [http://dx.doi.org/10.1016/S0009-2797\(02\)00164-3](http://dx.doi.org/10.1016/S0009-2797(02)00164-3).
 55. Kisker C, Schindelin H, Pacheco A, Wehbi WA, Garrett RM, Rajagopalan KV, Enemark JH, Rees DC. 1997. Molecular basis of sulfite oxidase deficiency from the structure of sulfite oxidase. *Cell* 91:973–983. [http://dx.doi.org/10.1016/S0092-8674\(00\)80488-2](http://dx.doi.org/10.1016/S0092-8674(00)80488-2).
 56. Thöny B, Auerbach G, Blau N. 2000. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 347:1–16. <http://dx.doi.org/10.1042/0264-6021:3470001>.
 57. Gourley DG, Schüttelkopf AW, Leonard GA, Luba J, Hardy LW, Beverley SM, Hunter WN. 2001. Pteridine reductase mechanism correlates pterin metabolism with drug resistance in trypanosomatid parasites. *Nat Struct Biol* 8:521–525. <http://dx.doi.org/10.1038/88584>.
 58. Pribat A, Blaby IK, Lara-Nunez A, Gregory JF, III, de Crecy-Lagard V, Hanson AD. 2010. FolX and FolM are essential for tetrahydropterin synthesis in *Escherichia coli* and *Pseudomonas aeruginosa*. *J Bacteriol* 192:475–482. <http://dx.doi.org/10.1128/JB.01198-09>.
 59. Jeffery J, Cummins L, Carlquist M, Jörnvall H. 1981. Properties of sorbitol dehydrogenase and characterization of a reactive cysteine residue reveal unexpected similarities to alcohol dehydrogenases. *Eur J Biochem* 120:229–234. <http://dx.doi.org/10.1111/j.1432-1033.1981.tb05693.x>.
 60. Ensor CM, Tai HH. 1991. Site-directed mutagenesis of the conserved tyrosine 151 of human placental NAD⁺-dependent 15-hydroxyprostaglandin dehydrogenase yields a catalytically inactive enzyme. *Biochem Biophys Res Commun* 176:840–845. [http://dx.doi.org/10.1016/S0006-291X\(05\)80262-1](http://dx.doi.org/10.1016/S0006-291X(05)80262-1).
 61. Kim J, Heindl JE, Fuqua C. 2013. Coordination of division and development influences complex multicellular behavior in *Agrobacterium tumefaciens*. *PLoS One* 8:e56682. <http://dx.doi.org/10.1371/journal.pone.0056682>.
 62. Li G, Brown PJ, Tang JX, Xu J, Quardokus EM, Fuqua C, Brun YV. 2012. Surface contact stimulates the just-in-time deployment of bacterial adhesins. *Mol Microbiol* 83:41–51. <http://dx.doi.org/10.1111/j.1365-2958.2011.07909.x>.
 63. Reed LS, Archer MC. 1980. Oxidation of tetrahydrofolic acid by air. *J Agric Food Chem* 28:801–805. <http://dx.doi.org/10.1021/jf60230a044>.
 64. Wuebbens MM, Rajagopalan KV. 1995. Investigation of the early steps of molybdopterin biosynthesis in *Escherichia coli* through the use of in vivo labeling studies. *J Biol Chem* 270:1082–1087. <http://dx.doi.org/10.1074/jbc.270.3.1082>.
 65. Leimkühler S, Wuebbens MM, Rajagopalan KV. 2011. The history of the discovery of the molybdenum cofactor and novel aspects of its biosynthesis in bacteria. *Coord Chem Rev* 255:1129–1144. <http://dx.doi.org/10.1016/j.ccr.2010.12.003>.
 66. Curtis PD, Brun YV. 2014. Identification of essential alphaproteobacterial genes reveals operational variability in conserved developmental and cell cycle systems. *Mol Microbiol* 93:713–735. <http://dx.doi.org/10.1111/mmi.12686>.
 67. Workun GJ, Moquin K, Rothery RA, Weiner JH. 2008. Evolutionary persistence of the molybdopyranopterin-containing sulfite oxidase protein fold. *Microbiol Mol Biol Rev* 72:228–248. <http://dx.doi.org/10.1128/MMBR.00041-07>.
 68. Kanjee U, Ogata K, Houry WA. 2012. Direct binding targets of the stringent response alarmone (p)ppGpp. *Mol Microbiol* 85:1029–1043. <http://dx.doi.org/10.1111/j.1365-2958.2012.08177.x>.
 69. Potrykus K, Cashel M. 2008. (p)ppGpp: still magical? *Annu Rev Microbiol* 62:35–51. <http://dx.doi.org/10.1146/annurev.micro.62.081307.162903>.
 70. Tuckerman JR, Gonzalez G, Sousa EH, Wan X, Saito JA, Alam M, Gilles-Gonzalez MA. 2009. An oxygen-sensing diguanylate cyclase and phosphodiesterase couple for c-di-GMP control. *Biochemistry* 48:9764–9774. <http://dx.doi.org/10.1021/bi901409g>.
 71. Chang AL, Tuckerman JR, Gonzalez G, Mayer R, Weinhouse H, Volman G, Amikam D, Benziman M, Gilles-Gonzalez MA. 2001. Phosphodiesterase A1, a regulator of cellulose synthesis in *Acetobacter xylinum*, is a heme-based sensor. *Biochemistry* 40:3420–3426. <http://dx.doi.org/10.1021/bi0100236>.
 72. Qi Y, Rao F, Luo Z, Liang ZX. 2009. A flavin cofactor-binding PAS domain regulates c-di-GMP synthesis in AxDCG2 from *Acetobacter xylinum*. *Biochemistry* 48:10275–10285. <http://dx.doi.org/10.1021/bi901121w>.
 73. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, Semenitz E, Dierich MP, Wachter H. 1993. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. *FEBS Lett* 321:89–92. [http://dx.doi.org/10.1016/0014-5793\(93\)80627-7](http://dx.doi.org/10.1016/0014-5793(93)80627-7).
 74. Murr C, Widner B, Wirleitner B, Fuchs D. 2002. Neopterin as a marker for immune system activation. *Curr Drug Metab* 3:175–187. <http://dx.doi.org/10.2174/1389200024605082>.
 75. Hoffmann G, Schobersberger W, Frede S, Pelzer L, Fandrey J, Wachter H, Fuchs D, Grote J. 1996. Neopterin activates transcription factor nuclear factor-kappa B in vascular smooth muscle cells. *FEBS Lett* 391:181–184. [http://dx.doi.org/10.1016/0014-5793\(96\)00729-6](http://dx.doi.org/10.1016/0014-5793(96)00729-6).
 76. Gostner JM, Becker K, Fuchs D, Sucher R. 2013. Redox regulation of the immune response. *Redox Rep* 18:88–94. <http://dx.doi.org/10.1179/1351000213Y.0000000044>.
 77. Stewart PS, Franklin MJ. 2008. Physiological heterogeneity in biofilms. *Nat Rev Microbiol* 6:199–210. <http://dx.doi.org/10.1038/nrmicro1838>.
 78. Heckel BC, Tomlinson AD, Morton ER, Choi JH, Fuqua C. 2014. *Agrobacterium tumefaciens* ExoR controls acid response genes and impacts exopolysaccharide synthesis, horizontal gene transfer, and virulence gene expression. *J Bacteriol* 196:3221–3233. <http://dx.doi.org/10.1128/JB.01751-14>.
 79. Allen KD, Xu H, White RH. 2014. Identification of a unique radical S-adenosylmethionine methylase likely involved in methanopterin biosynthesis in *Methanocaldococcus jannaschii*. *J Bacteriol* 196:3315–3323. <http://dx.doi.org/10.1128/JB.01903-14>.